H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc.

CourtDistrict Court, D. Nevada
DecidedJanuary 23, 2020
Docket2:16-cv-02148
StatusUnknown

This text of H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc. (H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc., (D. Nev. 2020).

Opinion

1 UNITED STATES DISTRICT COURT

2 DISTRICT OF NEVADA

3 H&H PHARMACEUTICALS, LLC, ) 4 ) Plaintiff, ) Case No.: 2:16-cv-02148-GMN-VCF 5 vs. ) 6 ) ORDER CHATTEM CHEMICALS, INC., et al., ) 7 ) Defendants. ) 8 ) 9 10 Pending before the Court is the Motion to Dismiss, (ECF No. 15), filed by Defendants 11 Chattem Chemicals, Inc. (“Chattem”) and Sun Pharmaceutical Industries, Inc. (“Sun”) 12 (collectively, “Defendants”). Plaintiff H&H Pharmaceuticals, LLC (“Plaintiff”) filed a 13 Response, (ECF No. 22), and Defendants filed a Reply, (ECF No. 27). For the reasons 14 discussed below, Defendants’ Motion to Dismiss is GRANTED in part and DENIED in part. 15 I. BACKGROUND 16 This case is a dispute concerning the rights and obligations arising from a settlement 17 agreement and a nondisclosure agreement entered into by Plaintiff and Chattem. In its 18 Amended Complaint, (ECF No. 8), Plaintiff makes the following allegations. 19 Plaintiff H&H was founded in 1999 by Richard Herman (“Herman”) and Jacob Hack 20 (“Hack”). (Am. Compl. ¶ 9, ECF No. 8). Prior to 1979, Hack developed, and then contributed 21 to Plaintiff in 1999, chemistry processes for converting certain substances into opiate-based raw 22 materials. (Id. ¶ 10). These processes and conversion methods were not available on the open 23 marketplace or generally publicly known. (Id.). Plaintiff further alleges that it owns, inter alia, 24 confidential information, including trade secrets, as well as other designs, technology, 25 strategies, and plans with respect to its conversion methods (collectively, the “H&H Confidential Information”). (Id. ¶ 12). 1 Chattem “manufactures a variety of active pharmaceutical ingredients (APIs) and 2 performance chemicals used in consumer and industrial markets.” (Id. ¶ 15). In late 2000, 3 Plaintiff and Chattem entered into a nondisclosure agreement (the “NDA”) that the parties 4 would abide by when sharing confidential technology and trade secret information. (Id. ¶¶ 17, 5 18). On December 5, 2000, Plaintiff disclosed the H&H Confidential Information to Chattem. 6 (Id. ¶ 22). On December 6, 2000, Plaintiff, “by and through its managers Herman and Hack, 7 verbally entered into a partnership agreement with Chattem, by and through David Blum 8 (“Blum”), Chattem’s Vice President, thereby creating a partnership” between Plaintiff and 9 Chattem. (Id. ¶ 23). Plaintiff avers that in July 2001, the president of Chattem’s holding 10 company sent Herman and Hack a letter reiterating the terms of the partnership that were 11 originally discussed on December 6, 2000. (Id. ¶ 26). “Specifically, the letter mentioned that 12 the arrangement is a fifty/fifty (50%/50%) joint venture.” (Id.). On March 15, 2006, Blum 13 “sent a letter to [Plaintiff] denying the existence of a contractual relationship between Chattem 14 and [Plaintiff]. In the correspondence, Blum states that ‘no such relationship exists,’ other than 15 that described” in the NDA. (Id. ¶ 29). According to Plaintiff, “Chattem breached the 16 partnership agreement by failing to provide [Plaintiff] with 50% of its profits, which instigated 17 the initial lawsuit” between Plaintiff and Chattem, H&H Pharmaceuticals, LLC v. Chattem 18 Chemicals, Inc., et al., 2:07-cv-00430-JCM-RJJ (the “Initial Lawsuit”). (Id. ¶ 30). 19 In October 2007, Plaintiff and Chattem settled their dispute in the Initial Lawsuit and 20 entered into a settlement agreement (the “Settlement Agreement”). (Id. ¶ 31). Under Section 6 21 of the Settlement Agreement, “all provisions of the NDA shall remain in full force and effect 22 and shall in no manner, other than with respect to Plaintiff’s release, be diminished.” (Id. ¶ 33). 23 Section 8 states that “beginning on the Effective Date, which is October 10, 2007, ‘for the 24 succeeding five (5) years thereafter, . . . Defendants shall certify on the first Business Day after 25 expiration of each twelve-month . . . period’ that they are in compliance with the Settlement 1 Agreement and the NDA.” (Id. ¶ 34). According to Plaintiff, Section 24 “states that potential 2 purchasers of Chattem or a Controlling Interest in Chattem must assume Chattem’s obligations 3 of both the Settlement Agreement and the NDA (the “Assumption Condition”). Furthermore, 4 Chattem ‘shall provide Plaintiff with a statement accepting the Assumption Conditions from 5 the Buyer upon the closing of any such sale.’” (Id. ¶ 35). 6 Plaintiff alleges that from 2008 to 2012, Plaintiff received a “Certification Letter” from 7 Chattem, “representing that Chattem was still complying with all of the terms of the Settlement 8 Agreement and the NDA.” (Id. ¶ 36). However, in October 2013, Plaintiff discovered that 9 Chattem was purchased by Sun on November 25, 2008. (Id. ¶ 45). Plaintiff then learned that 10 Sun was applying for certain licenses using Plaintiff’s processes, “which evidences Chattem’s 11 violation of the NDA.” (Id. ¶ 46). 12 On August 9, 2016, Plaintiff filed its Complaint in Clark County District Court. 13 (Complaint, Ex. A to Petition for Removal, ECF No. 1). Defendants subsequently removed 14 based on diversity jurisdiction. (Petition for Removal, ECF No. 1). Plaintiff then filed its 15 Amended Complaint, (ECF No. 8), setting forth the following causes of action: (1) breach of 16 contract against Chattem; (2) contractual breach of the implied covenant of good faith and fair 17 dealing against Chattem; (3) tortious breach of the implied covenant of good faith and fair 18 dealing against Chattem; (4) breach of fiduciary duty against Chattem; (5) constructive fraud 19 against Chattem; (6) fraudulent concealment against Chattem and Sun; (7) fraudulent 20 misrepresentation against Chattem and Sun; (8) negligent misrepresentation against Chattem 21 and Sun; (9) negligence against Chattem and Sun; (10) unjust enrichment against Chattem and 22 Sun; and (11) civil conspiracy against Chattem and Sun. Defendants now move to dismiss all 23 of Plaintiff’s claims for failure to state a claim upon which relief can be granted. 24 /// 25 /// 1 II. LEGAL STANDARD 2 A. Rule 12(b)(6) 3 Dismissal is appropriate under Federal Rule of Civil Procedure (“Rule”) 12(b)(6) where 4 a pleader fails to state a claim upon which relief can be granted. Fed. R. Civ. P. 12(b)(6); Bell 5 Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007). When considering a motion to dismiss under 6 Rule 12(b)(6) for failure to state a claim, dismissal is appropriate only when the complaint does 7 not give the defendant fair notice of a legally cognizable claim and the grounds on which it 8 rests. See Twombly, 550 U.S. at 555. In considering whether the complaint is sufficient to state 9 a claim, the Court will take all material allegations as true and construe them in the light most 10 favorable to the plaintiff. See NL Indus., Inc. v. Kaplan, 792 F.2d 896, 898 (9th Cir. 1986). 11 The Court, however, is not required to accept as true allegations that are merely 12 conclusory, unwarranted deductions of fact, or unreasonable inferences. See Sprewell v. Golden 13 State Warriors, 266 F.3d 979, 988 (9th Cir. 2001). A formulaic recitation of a cause of action 14 with conclusory allegations is not sufficient; a plaintiff must plead facts showing that a 15 violation is plausible, not just possible. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing 16 Twombly, 550 U.S. at 555) (emphasis added).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Tellabs, Inc. v. Makor Issues & Rights, Ltd.
551 U.S. 308 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Cafasso v. General Dynamics C4 Systems, Inc.
637 F.3d 1047 (Ninth Circuit, 2011)
Nl Industries, Inc. v. Stuart M. Kaplan
792 F.2d 896 (Ninth Circuit, 1986)
John Desoto v. Yellow Freight Systems, Inc.
957 F.2d 655 (Ninth Circuit, 1992)
Marder v. Lopez
450 F.3d 445 (Ninth Circuit, 2006)
Gary Davis v. Hsbc Bank Nevada, N.A.
691 F.3d 1152 (Ninth Circuit, 2012)
Aluevich v. Harrah's
660 P.2d 986 (Nevada Supreme Court, 1983)
Collins v. Burns
741 P.2d 819 (Nevada Supreme Court, 1987)
State v. Grannis
900 P.2d 1 (Arizona Supreme Court, 1995)
Lipshie v. Tracy Investment Co.
566 P.2d 819 (Nevada Supreme Court, 1977)
Epperson v. Roloff
719 P.2d 799 (Nevada Supreme Court, 1986)

Cite This Page — Counsel Stack

Bluebook (online)
H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/hh-pharmaceuticals-llc-v-chattem-chemicals-inc-nvd-2020.